RxDoctor Payments Data

John Cecconi, MD

Family Medicine · Syracuse, NYNPI 1477934362

Payments from drug & device makers

$3,127in general payments, 2019–2025

Across 162 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$544
  • Pfizer$322
  • Lilly USA, LLC$308
  • Novo Nordisk$307
  • Regeneron$292
  • GSK$246
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$2568%
  • Food & beverage$2,87192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,127 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$53,192
Medicare patients
193
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$99,746
EliquisApixaban60$73,121
TrulicityDulaglutide67$66,152
JardianceEmpagliflozin49$48,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$39,318
XareltoRivaroxaban16$15,626
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,106
EntrestoSacubitril/Valsartan14$9,572
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,547
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,213
Janumet XrSitagliptin Phos/Metformin Hcl11$6,199
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,170
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$5,905
Breo ElliptaFluticasone/Vilanterol15$5,472
ShingrixVaricella-Zoster Ge/As01b/Pf19$3,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$307$99,74688 claims
PfizerEliquis$322$73,12160 claims
Lilly USA, LLCTrulicity$308$66,15267 claims
Boehringer IngelheimJardiance, Stiolto Respimat$160$59,86465 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$246$54,80192 claims
NovartisEntresto$20$9,57214 claims
AstraZenecaBreztri Aerosphere$218$9,54716 claims
MerckJanumet Xr$26$6,19911 claims
AbbVieSynthroid$544$2,26025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →